• Azilsartan Medoxomil Monopotassium: Innovations in AT1 Antag

  2026-06-02

  Explore how Azilsartan medoxomil monopotassium (TAK 491) is transforming essential hypertension research with its unique receptor dynamics and assay guidance. This in-depth analysis unveils new decision frameworks for cardiovascular studies and practical dosing, exceeding standard experimental workflows.

• Targeting GLI2: GANT61 and the Future of Tumor Immune Evasio

  2026-06-01

  Explore a strategic, mechanistic roadmap for translational cancer researchers deploying GANT61—a selective GLI inhibitor—to tackle tumor immune evasion and therapy resistance. This thought-leadership article synthesizes emerging evidence, actionable workflow insights, and clinical perspectives, distinguishing itself from standard product guides by connecting GLI2-driven immunosuppression with innovative therapeutic strategies.

• Metabolic Alterations in Posterior Fossa Malignancies: Insig

  2026-06-01

  This dissertation by Derek Dang provides a detailed examination of metabolic shifts in posterior fossa malignancies, moving beyond the classical Warburg effect to identify novel alterations in cancer cell metabolism. The work delivers methodological rigor and new perspectives for phosphoproteomic research, directly informing strategies for preserving protein phosphorylation states during sample preparation.

• Losartan: Selective Angiotensin II Receptor Antagonist for R

  2026-05-31

  Losartan is a selective angiotensin II receptor antagonist widely used in hypertension and cardiovascular physiology research. It precisely inhibits AT1-mediated signaling and vascular smooth muscle cell proliferation. This compound is a validated tool for dissecting angiotensin II signaling in both in vitro and in vivo models.

• 5-Aminolevulinic acid HCl: Unraveling Heme Biosynthesis and

  2026-05-30

  Explore the scientific nuances of 5-Aminolevulinic acid HCl as an intermediate in heme biosynthesis and its pivotal role in pathogenic immune evasion. This article delivers deep insights for cancer and infection research, offering analysis not found in existing content.

• Pharmacokinetics of Non-Nucleosidic DNMT Inhibitor RG108 In

  2026-05-29

  This study provides the first detailed pharmacokinetic analysis of RG108, a non-nucleosidic DNA methyltransferase inhibitor, in a rat model. The results establish RG108’s in vivo bioavailability, tissue distribution, and support its utility in epigenetic research beyond oncology.

• Cytarabine (AraC): Mechanistic Depth and Emerging Assay Hori

  2026-05-29

  Explore the advanced molecular mechanisms of Cytarabine (AraC) as an apoptosis inducer in leukemia research. This article uniquely bridges foundational DNA damage science with new insights on necroptosis pathway research for next-generation assay design.

• Modeling HSV-1 Latency in Human iPSC-Derived Sensory Neurons

  2026-05-28

  This study establishes a scalable human sensory neuron model from inducible pluripotent stem cells for investigating herpes simplex virus 1 (HSV-1) latency and reactivation. The model enables direct study of neuron-intrinsic mechanisms underlying HSV-1 latency, addressing key limitations of animal systems and paving the way for targeted antiviral research.

• Mubritinib (TAK 165): Mitochondrial Targeting for Translatio

  2026-05-28

  This thought-leadership article explores the evolving role of Mubritinib (TAK 165) as a mitochondrial electron transport chain complex I inhibitor in the context of translational oncology. By integrating mechanistic insights, recent experimental findings, and strategic workflow guidance, we delineate how Mubritinib is reshaping paradigms in cancer biology—specifically in acute myeloid leukemia, primary effusion lymphoma, and HER2-driven solid tumors. The discussion synthesizes new data on mitochondrial disruption and therapeutic synergy, highlights APExBIO’s product innovation, and provides actionable recommendations for researchers tackling drug resistance and assay reproducibility.

• Angiotensin II (A1042): Technical Guidance for Lab Research

  2026-05-27

  Angiotensin II (SKU A1042) addresses reproducibility and mechanistic fidelity in hypertension, vascular remodeling, and abdominal aortic aneurysm models where precise GPCR agonist activity is required. This reference provides actionable technical guidance for optimal use and highlights boundaries such as incompatibility with diagnostic or clinical workflows.

• Machine Learning Uncovers Polymer Micelle Chemistry for Lung

  2026-05-27

  This study systematically investigates how the amine type in polymer micelles determines mRNA binding, delivery efficacy, and tissue selectivity, using a combination of experimental assays and machine learning. The findings reveal that fine-tuning amine chemistry optimizes both in vitro and in vivo mRNA delivery, with direct implications for targeted gene therapies and rational vector design.

• Angiotensin II in Abdominal Aortic Aneurysm Models: Mechanis

  2026-05-26

  Explore how Angiotensin II drives abdominal aortic aneurysm (AAA) pathogenesis and enables advanced vascular research. This in-depth analysis reveals unique mechanistic insights and optimized protocols for hypertension and vascular smooth muscle cell hypertrophy studies.

• Marine Peptides Counteract Angiotensin II-Induced Endothelia

  2026-05-26

  The referenced study identifies two peptides from Harpadon nehereus bone that mitigate Angiotensin II-induced oxidative stress and dysfunction in human endothelial cells via the AKT/eNOS and Nrf2 pathways. This work advances understanding of natural peptide interventions for vascular injury, offering mechanistic insights relevant to hypertension and cardiovascular remodeling research.

• Trelagliptin Succinate: Precision Modulation of Insulin Sign

  2026-05-25

  Explore how Trelagliptin succinate advances type 2 diabetes research through selective DPP-4 inhibition and targeted PI3K/Akt/GLUT4 pathway modulation. This article offers an in-depth, mechanistic perspective and practical assay guidance distinct from existing resources.

• Azilsartan Medoxomil: Superior Blood Pressure Reduction in M

  2026-05-25

  A systematic literature review and network meta-analysis demonstrates that azilsartan medoxomil (TAK 491) achieves the greatest reduction in both systolic and diastolic blood pressure among first-line antihypertensives in mild-to-moderate hypertension. These results underscore its value for essential hypertension treatment research and protocol optimization.

450 records 16/30 page Previous Next First page 上5页 1617181920 下5页 Last page